The full version of this article
may be viewed online at
jop.ascopubs.org

University of California Los Angeles (UCLA)
School of Nursing; UCLA Schools of
Medicine and Public Health; and UCLA
Jonsson Comprehensive Cancer Center,
Los Angeles, CA

Corresponding author: Huibrie C. Pieters,
PhD, DPhil, RN, School of Nursing, Tiverton
Ave #4-956, University of California
Los Angeles, Los Angeles, CA 90095;
e-mail: hpieters@sonnet.ucla.edu.

Disclosures provided by the authors are
available with this article at
jop.ascopubs.org.

“Winging It”: How Older Breast Cancer Survivors Persist With Aromatase Inhibitor Treatment

Eden R. Brauer, PhD, RN, Patricia A. Ganz, MD, and Huibrie C. Pieters, PhD, DPhil, RN

QUESTION ASKED: How do older breast cancer survivors make decisions about persisting with aromatase inhibitors (AIs) and manage treatment-related challenges?

SUMMARY ANSWER: Essential to women’s decision making to persist with AIs was the reality of acknowledging that taking the pill marked a new phase of treatment rather than the end of the cancer experience. When women experienced treatment-related challenges, such as adverse effects that affected quality of life, they relied on self-management strategies rather than the support of their medical providers.

WHAT WE DID: Eligible women were recruited from a variety of settings. Single-session, in-depth interviews using a semistructured interview guide were conducted with women age 65 years or older who were treated for locoregional breast cancer and had started an AI 4 to 36 months before study enrollment. Data analysis followed the systematic guidelines of constructivist grounded theory.

WHAT WE FOUND: A total of 27 women were interviewed, and they reported that integrating the AI treatment into daily life posed many challenges. The adverse effects of AIs were difficult to disentangle from what women attributed to comorbid conditions or getting older. This challenge in attribution, coupled with less frequent contact with their oncology team, resulted in many women “winging it” or persisting with the AI despite significant struggles. In particular, participants expressed concerns about the impact of perceived adverse effects on quality of life and ability to carry out social roles. Many reported lack of professional guidance or support with respect to persisting with the AI, especially when adverse effects were present, and relied on a variety of self-management strategies to maintain treatment with the AI. The women often described circumstances, or potential tipping points, under which they might discontinue the AI prematurely.

BIAS, CONFOUNDING FACTOR(S), DRAWBACKS: Although they comprised a small sample limited to one geographic region of the country, the women were from diverse racial, cultural, and social backgrounds that added depth to their experiences of decision making.

REAL-LIFE IMPLICATIONS: Older breast cancer survivors who are persisting with AI treatment may be “winging it,” attempting to self-manage adverse effects on their own, and may be at risk for early discontinuation. Participants needed AI-specific education, support, and practical self-management strategies to improve both medication persistence and quality of life. We offer possible strategies to enhance clinical management and adherence. **JOP**

DOI: [10.1200/JOP.2016.011767](https://doi.org/10.1200/JOP.2016.011767);
published online ahead of print at
jop.ascopubs.org on September 13,
2016.

“Winging It”: How Older Breast Cancer Survivors Persist With Aromatase Inhibitor Treatment

Eden R. Brauer, PhD, RN, Patricia A. Ganz, MD, and Huibrie C. Pieters, PhD, DPhil, RN

University of California Los Angeles (UCLA) School of Nursing; UCLA Schools of Medicine and Public Health; and UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA

Abstract

Purpose

Aromatase inhibitors (AIs) are an important and effective hormonal adjuvant treatment for early-stage breast cancer. Up to 50% of women stop AIs prematurely, missing a valuable therapeutic intervention.

Patients and Methods

We used grounded theory methodology to conduct in-depth, semistructured interviews and analyze data among patients with breast cancer diagnosed at age 65 years or older who were receiving an AI. The goal of the interviews was to understand decision making regarding persisting with AIs. Interview transcripts were systematically analyzed to identify emergent categories and relationships.

Results

Interviews were conducted with 27 women. After completion of primary treatment, women in our sample found themselves “winging it” as they faced substantial struggles with infrequent support during this new phase of the cancer trajectory. Self-management of AI adverse effects occurred in the contexts of older age and early survivorship. “Bearing it” emerged as another important management process regarding the impact of AIs on quality of everyday life. The complex decision to persist with the AI involved weighing the possibility of a cancer-free future against the burden of adverse effects. Women relied on informal networks for support, rather than oncology providers, highlighting the need for practical self-management strategies. The notion of a tipping point in persistence revealed their susceptibility to early discontinuation.

Conclusion

This study provides insight into potential decisional pathways leading to early discontinuation of AIs among older women with breast cancer. Better support is needed for these women.

INTRODUCTION

With the aging of the US population, breast cancer among women age 65 years or older is expected to increase considerably, from 1,068,000 patient cases in 2010 to 2,858,000 in 2020.¹ Currently, the median age at diagnosis is 61 years, with incidence rates for women age 60 years or older on the rise since the mid 2000s.² According to recent national

estimates, women age 60 years or older will account for 131,430 (56%) new cases of invasive breast cancer and 70% of all deaths resulting from breast cancer in the United States annually.² This disproportionate death rate is of particular concern because older women are usually diagnosed with more-treatable breast cancers than younger women.³ Antihormonal treatments, such as aromatase

DOI: [10.1200/JOP.2016.011767](https://doi.org/10.1200/JOP.2016.011767);
published online ahead of print at
jop.ascopubs.org on September 13,
2016.

inhibitors (AIs), decrease recurrence and dramatically improve survival among women with hormone-positive tumors.⁴⁻⁷ Unfortunately, early discontinuation of and nonadherence to these antihormonal treatments are common in women age 65 years or older and directly affect breast cancer outcomes.⁸⁻¹⁰ Limited evidence suggests early discontinuation of hormonal treatments is associated with older age^{11,12} and adverse effects^{13,14} and usually occurs within the first year, but may also occur in subsequent years.^{15,16} However, underlying reasons for these decisions remain poorly understood.^{13,17}

Because AIs are oral medications that are self-administered in the home setting and started during the transitional survivorship period,^{18,19} we wanted to understand what factors are associated with persistence and how these medications fit into the broader life context of older breast cancer survivors from the perspectives of the women themselves. However, we found only two studies, both conducted outside the United States, that used qualitative methodologies to investigate adherence from the women's own perspectives, and neither was solely focused on AIs or women age older than 65 years.^{20,21} Thus, we explored how survivors of early-stage breast cancer, age 65 years and older, made decisions about persisting with AIs, including specific challenges as well as attempts to manage them.

PATIENTS AND METHODS

Procedures and Participant Recruitment

Qualitative methodology, guided specifically by constructivist grounded theory, was used to explore the processes of persisting with AIs from the perspectives of this sample of older women.²² Eligible women were at least 65 years of age when diagnosed with locoregional (stage I, II, or III) breast cancer, were responsible for taking their own medication, and had started an AI as adjuvant treatment 4 to 36 months before study enrollment. After receiving approval from the University of California Los Angeles Institutional Review Board, we recruited women with flyers in hospitals, community centers, and breast clinics, as well as mailings using cancer registries in southern California, from August 2013 to September 2015. A total of 237 women inquired about the study and were screened for eligibility and interest in the study. Of these, 209 were ineligible to participate, and of the remaining 28 women, 27 agreed to participate. The main reasons for ineligibility were never receiving an AI and a prior history of cancer.

Data Collection and Analysis

After obtaining signed consent for interviews and medical record release, individual, in-person, single-session interviews were conducted (by H.C.P.) using a semistructured interview guide (Table 1). Most interviews took place in participants' homes (n = 20) based on their preference. The average length of each interview was 87.4 minutes. Interviews were digitally audio recorded and then transcribed verbatim, checked for accuracy, and deidentified by the research team. Additional pertinent information was abstracted from the medical record. Other sources of data included demographic variables obtained by a self-report questionnaire as well as field notes. Three members of the research team systematically and independently coded the data, using initial coding, followed by focused coding to identify emergent categories and theoretic coding to determine relationships among them. Regular meetings among the coders occurred to enhance methodologic rigor and discuss discrepancies, as well as develop categories. Triangulation across analysts facilitated deeper understanding by approaching the data in multiple ways.²³ Analytic techniques such as constant comparison, memo writing, diagramming, and mapping were implemented throughout to deepen analysis. The Atlas.ti software program (<http://atlasti.com>) was used for data management.

RESULTS

Sample Characteristics

The 27 women were diagnosed on average at 72 years of age and had diverse racial, ethnic, cultural, marital, and socioeconomic backgrounds (Table 2). Medical record review indicated that all participants had at least one other chronic illness, with more than 75% (21 of 27) having three or more chronic illnesses. Most participants (n = 21) received care at an academic medical center or affiliate clinic. Fifteen women had stage I disease, whereas the rest had been diagnosed with stage II or III disease. In terms of primary treatment, the most common surgery was lumpectomy, and more women had undergone radiotherapy than chemotherapy, although these categories were not mutually exclusive. At the time of the interviews, women had completed primary treatment on average 14.1 months earlier and had been receiving an AI for an average of 13.3 months. At the time of the study, participants took one to 13 prescription pills per day (average, 4.6 pills), including the AI. AI-related adverse effects were documented in the medical records of 13 women; however, the

Table 1. Examples of Conversational Interview Questions

Question
What are some of your reasons for deciding to take the (the name the participant used to describe her AI) treatment? Prompt: Do you understand the purpose of this medication as part of your treatment? If so, how? Prompt: What are your goals with taking the (name)?
You described that the (her word) is an adverse effect of the (name); how have you made decisions about continuing treatment when adverse effect(s) arose? Prompt: What or who has helped you to continue with the (name) despite experiencing this adverse effect?
Please give everyday examples of how the adverse effects have influenced your life.
Have you ever had a time when you considered stopping or taking a break from the medication? Prompt: If so, can you tell me about that time?
How often do you see your oncologist/oncology provider now? Do you typically discuss adverse effects at these appointments? Prompt (if yes): What helps you to discuss the adverse effects with your physician? What would make it easier to do so? Prompt (if no): What about the experience makes it hard for you to talk about the adverse effects with your provider?

Abbreviation: AI, aromatase inhibitor.

vast majority discussed experiencing adverse effects during the interviews.

Overall, the women in this sample described the following key factors in their decision to persist with an AI: being older, proceeding from primary treatment to “winging it” in the next phase of cancer survivorship, and understanding adverse effects. Participants also perceived that persisting with the AI was accompanied by struggling and bearing adverse effects, and they foresaw potential tipping points that could lead to premature discontinuation of the treatment.

Context Matters: Older Age and a New Phase of Treatment

Persisting with the AI occurred in the context of an older life stage and the period of adjustment that follows completion of primary treatment. The older age of the women in our sample was important to their experience with taking the AI. In particular, most of these older women were well versed in managing health conditions and taking oral medications in the home setting. Therefore, before starting the AI, most participants had a well-established home medication routine, such as a daily pillbox. Familiarity with taking medications also meant that these women had prior experience with adverse effects. They understood that recognition and management of these adverse effects were worthwhile endeavors to reap the benefits of a medication. Although one woman occasionally skipped a dose to manage adverse effects, explaining, “Maybe I won’t take that today and see if it helps,” the women generally took the AI medication as prescribed. No participant identified cost as a barrier to receiving the AI.

When the women started the AI, they, along with their friends and family, understood cancer treatment to be over and expected to leave the cancer experience behind them. In fact, it was during their recovery from primary treatment that many women reported that they first learned about the AI, and some felt frustrated by this unexpected extension of treatment. The shift from “receiving” surgery, chemotherapy, and radiotherapy to taking a pill signified a sharp contrast between the AI experience and primary cancer treatments. Also, unlike surgery, chemotherapy, and radiotherapy, the AI represented a treatment that would continue for many years. Women described surprise that such a small, seemingly insignificant pill could hold so much promise.

Navigating this phase while interacting less frequently with the oncology team resulted in new challenges. One participant described how the familiar and reassuring footholds were pulled away just as she was starting the AI. She said, “You feel like you don’t have all the structures we talked about before, so now you’re winging it, and that’s scary” (Table 3). Thus, AI therapy began during a blurry period in which women wondered whether they were still recovering from primary treatment or experiencing new symptoms related to this new medication.

Inherent in the AI trajectory was the challenge of integrating this tiny pill, so named by several women, into daily life and acknowledging that the AI marked a new phase rather than the end of the cancer experience. This new phase needed to be tolerable in a different way, demanding a marathon rather than sprint mentality and allowing the woman to resume social roles such as wife, mother, grandmother, employee, or volunteer.

Table 2. Sociodemographic and Clinical Characteristics (N = 27)

Characteristic	No.	Mean	Range
Age at diagnosis, years		71.8	65-89
Age at interview, years		73.3	66-91
Months since completion of primary treatment (at interview)		14.1	6-36
Months since starting AI (at interview)		13.3	5-36
Breast cancer stage			
I	15		
II	9		
III	3		
Primary treatments received			
Lumpectomy	19		
Lateral mastectomy	5		
Double mastectomy	3		
Radiotherapy	20		
Chemotherapy	7		
CCI		3.3	2-8
Marital status			
Divorced	4		
Never married	1		
Married or living as married	12		
Widowed	9		
Separated	1		
Education (highest completed)			
High school diploma	7		
Some college	2		
Bachelor's degree	9		
Some graduate school	3		
Graduate degree	6		
Annual household income, \$			
≤ 20,999	1		
21,000-40,999	5		
41,000-60,999	3		
61,000-80,999	8		
81,000-100,999	4		
≥ 101,000	6		

Abbreviations: AI, aromatase inhibitor; CCI, Charlson comorbidity index.

For women who experienced adverse effects, persisting with the AI brought on unique challenges without the same level of support they had had during primary treatment.

The main motivation for the women's initiation of and continuation with the AI was the possibility of a cancer-free future. The participants realized that the AI did not guarantee this outcome, and so it was not the promise of a cancer-free future but the possibility of one that motivated them. Compared with the fatal disease that breast cancer was when they were growing up, the possibility of a cancer-free future was reinforced by a changing breast cancer culture in which they saw many women surviving, talking more about it, and going on with their lives. As one woman explained, "You know when I was growing up, it was all hush-hush ... you whispered the word 'cancer' and now it's really in our vernacular." However, despite clear and focused motivation to start the AI, many women experienced burdensome adverse effects, such as hot flashes, joint pain, depression, skin and hair changes, and insomnia.

Disentangling Adverse Effects

For this sample of older women, adverse effects emerged as a noteworthy burden associated with taking the AI. Disentangling whether a physical or psychological change was an adverse effect of the AI, residual from primary treatment, an exacerbation of another medical condition, or simply a part of aging was challenging. The AI worsened some pre-existing conditions, such as joint pain or depression, and so the contribution of the AI was also unclear. As one woman said, "It's very hard for me to pinpoint what's causing what because I have all of these different [health conditions]." Interference with quality of life was emphasized as the most distressing aspect of the adverse effects. A participant for whom the adverse effects subsided over time explained, "What is important for me is to go back to my lifestyle, which is very active. And with the side effects, I would have been on that couch." The women expressed the most frustration when adverse effects acted as a barrier to normalcy and the ability to carry out social roles.

Struggling Despite Persisting

Despite describing good relationships with oncologists, our sample largely did not rely on them to help with adverse effects and did not perceive management of AI adverse effects as part of the oncologist's role. As women tried to re-establish their lives, many were comforted by the belief that the oncologist now had sicker patients for whom to care. Many women reported that the AI was not mentioned during follow-up oncology appointments, indicating to the women the medication

Table 3. Themes and Examples Related to Persisting With AIs Among Older Women

Theme	Example
Context of transitional survivorship	"And so, at that point, I'm done with my radiation, the chemo, with the surgery, with the whole deal. I'm kind of on my own a little bit You're also trying to get your footing ... you feel like you don't have all the structures we talked about before, so now you're winging it, and that's scary." "I thought I would be through after [primary treatment].... I was upset that it's going to drag on and on and on, but I do it."
Lack of AI discussion in oncology follow-up care	"I think that my understanding was, if there's side effects, we'll deal with them. And, in fact, when I went to see the oncologist for the last checkup, the subject didn't even come up. She just assumes I'm taking it, I guess.... And certainly no one has ever said to me, 'Are you thinking of stopping it?'"
Adverse effects as barrier to normalcy	"And I have two, three grandchildren. I love children.... So, when I see them, I want to play with them ... but physically I can't do it. So, that makes me—really upsets me. I think that's the thing."
Disentangling adverse effects from old age	"There is a little joint problem I'm having, and it's probably letrozole based. I say probably because I'm aging and I do have a little arthritis in my spine. But when I first wake in the morning, I'm more stiff than I have ever been, and we seem to attribute it to letrozole. Whether that's fair, I'm not sure."
Disentangling adverse effects from pre-existing conditions	"I have had depression [before cancer]. And, of course, the whole process doesn't exactly lead to [chuckles] So, I don't know if that's a side effect of the drug or not.... It's really hard to separate that [depression] from the actual cancer, so I don't know."
Weighing up	"I'm not enjoying it.... I'll put up with that to try to prevent a reoccurrence. [So when weighing things up,] Arimidex wins hopefully, that it's inhibiting my cancer from coming back." "It's a bad disease, but there many, many, many more survivors than ever before and I want to be a survivor.... If there are rules that you have to follow to survive, then I'm going to follow the rules even though I don't like the side effects."
Bearing the AI	"There's an expression in Japanese that says, 'It can't be helped.' So you're supposed to have the strength to go through it because it can't be helped.... It's not something that I can do anything about. I can't stop it. I can't change it. So, I have to deal with it." "I mean manage it? I don't know? That's it. Just live with it."
Avoiding additional medications	"[My physician] said that if [the hot flashes] were too intense, she could give me something that would sort of balance them out. And I said, 'Well, I don't want another pill.' I really don't want another pill. I take so much already, and I'm practically kept alive with chemicals as it is." "Well, the doctor said, 'Is it intolerable? Is it unbearable? Because I can give you some pills, but there are side effects to the pills.' ... But I said, 'I'm taking so many pills already. I'd rather not. If I can manage it, if I can tolerate it.'"
AI switching	"I just decided to stay with the Arimidex so that I don't have to go through another 3 to 6 months of getting used to the new side effects, if there were any. And apparently each of the inhibitors has side effects."
Tipping points	
Physical thresholds	"I understand that I could take it as much as I could bear it and if it's helping me. Well, if I start getting, you know, my bones deteriorating and things like that, losing a lot of hair, where I could see physical change in me, I will know that I will stop it."
Advances in medical research	"If some new research came out that said it [AI] was useless, then I would stop because I know that with some other drugs, they have these claims."

Abbreviation: AI, aromatase inhibitor.

was not important or that the oncologist assumed they were taking it. Instead, women often turned to nononcologist physicians whom they had known for a long time, such as a primary

care physician or gynecologist, with concerns about the AI. Although several women were offered additional medications to manage AI-related adverse effects, such as antidepressants

to help mitigate hot flashes, they were generally reluctant to add pills that might introduce their own unpredictable adverse effects into their daily routine. Nononcologist physicians were also helpful in offering encouragement and motivation. One woman explained how her primary care physician of many decades helped her understand the purpose and value of the AI when she mentioned wanting to discontinue because of her brittle nails.

Switching to another AI to manage adverse effects was an option that few women mentioned. In general, women were unenthusiastic about new medications with adverse effects that were potentially the same or worse, including alternative AIs. One woman who did try switching drugs ended up switching back to the original drug, whereas another woman considered switching but decided not to go through an adjustment period for another drug (Table 3). Some women incorporated their own supplements and herbs into their routine, but typically, this was something they found out about and initiated on their own and just ran the idea past their physician. The women strongly preferred to use practical lifestyle adjustments, rather than additional medications, to bear or tolerate AI adverse effects.

Bearing AI Adverse Effects

Adverse effects were unpleasant and intrusive but usually not unbearable. Many women acknowledged that adverse effects changed over time. Personal motivations and hopes for the future helped the women to soldier on and persist with the AI despite ongoing struggles. Through weighing the potential benefits of the drug with the discomforts of the adverse effects, women came to the decision to persist and reshifted their focus to make burdensome adverse effects more bearable. Women often discussed their struggles with fellow cancer survivors and shared practical tips that facilitated AI continuation through these informal channels. Tip sharing emerged as an important process that fellow breast cancer survivors used to share information and knowledge, typically to self-manage adverse effects or mitigate the impact of illness and treatment on daily life in the home setting. Through these supportive networks, women valued the process of combining their individual experiences and solutions they had figured out along the way and sharing that collective knowledge.

Tipping Points

Despite bearing the unpleasantness of adverse effects and persisting with the AI at the time of the interview, no participant, when asked, said that she would persist regardless.

Although women were willing to try the AI, many of them were able to articulate a threshold, a potential tipping point, at which they would discontinue or seriously consider discontinuing the AI. These thresholds largely pertained to adverse effects becoming unbearable or even painful, such as in the case of the woman who, considering the years ahead, stated, “He told me I had to take the pill for 5 years. But then, when I started having all these hot flashes, I thought, ugh, maybe not” (Table 3). However, this sample of older women also reflected on a lifetime in which they had witnessed profound changes in scientific knowledge, specifically medical research, and indicated that advances related to AIs in research could also affect their decision to continue or not.

DISCUSSION

To our knowledge, our study is unique in its exploration of the struggles that continuation of AI treatment involved for a group of older women. The interface of older age, cancer survivorship, and starting an AI posed distinct challenges to medication persistence for the women in our sample. Attempts have been made to support survivors as they transition from primary treatment; however, little precedent exists for management of AIs. In the context of gero-oncology, disentangling AI adverse effects from other aspects of older age, such as other medical conditions, slower recovery from primary treatment, and age-related changes themselves, complicates the AI experience for this group of women. Even in cases where women are misattributing their symptoms to adverse effects of the AI, the assumption clearly poses a threat to AI continuation if the AI is culpable from their perspective. When women start receiving AIs, primary therapy is completed, but women are beginning a new treatment, with its own adjustment period and potential adverse effects. The experience of receiving the AI differs from primary treatment, because women are responsible for taking the pill in the home setting for many years, with infrequent interaction with the oncology team. Therefore, the AI must be integrated into a woman’s daily life.

Our research used a lifespan perspective, which highlighted the distinct yet unmet needs of older women as they persisted with AIs. The broader context of older age and related aspects such as comorbidities, polypharmacy, and value of quality of life is essential to the AI experience of older women. Our findings are consistent with other research suggesting that adverse effects account for most of the burden associated with hormonal therapies.^{12,14,21} However, among older women, the adverse effects of AIs are difficult to disentangle from

comorbid conditions or what the women attribute to getting older. This challenge in attribution, coupled with less frequent contact with their oncology team, results in many women “winging it” or persisting with the AI without much-needed professional guidance or support. Given their older age, women in our sample were likely to know other breast cancer survivors and turned to these informal networks for camaraderie and the exchange of practical knowledge. Ultimately, women weighed the possibility of a cancer-free future against the discomfort that they associated with the pill and decided, at least for now, to bear it. This finding is consistent with the decisional balance seen in both older and younger women willing to tolerate the negative impact of antihormonal therapy on daily life to reduce the threat of cancer recurrence and death.^{20,24} Women engaged in efforts to make the AI experience more tolerable in terms of physical discomfort, as well as in terms of the impact of adverse effects on quality of life and sense of self.

While they persist with an AI, women also struggle and can often verbalize circumstances under which they might

discontinue the AI early, thus alerting us to the fluidity between women who are persisting with an AI and those who discontinue prematurely. The notion of a tipping point in their efforts to manage AI adverse effects identified this group as susceptible to discontinuing treatment before the recommended 10 years. Another important finding related to tipping points was the women’s awareness that medical research changes over time. It is noteworthy that this particular age cohort lived through the Women’s Health Initiative, which found that hormone replacement therapy carried more risk than previously thought. Women reflected on this experience as one in which they realized the unfixed nature of medical research. With respect to AIs, women understood that research is ongoing, and many unanswered questions remain. These findings have important clinical implications for AI continuation, especially in light of recent changes to the recommended duration of AI treatment from 5 to 10 years.

Older breast cancer survivors who are persisting with AI treatment may also be “winging it,” “bearing it,” and at risk

Table 4. Clinical Strategies for Women Who Are Persisting With AIs

Finding	Clinical Strategy
Women who are persisting are at risk of stopping	Acknowledgment: Take a minute to acknowledge that the woman is reducing her risk by continuing with the AI and offer encouragement
Women weigh potential benefits against burden of adverse effects	Help her focus on motivation: Reinforce clinical benefits of the AI and assess level of adverse effect burden at every appointment
Women tend not to initiate conversations about their concerns related to the AI	Start the AI conversation: Asking directly about the AI by name shows interest and conveys the value of the medication
Women experience changes in adverse effects over time	Ask each time: Acknowledging that adverse effects change over time and checking in about adverse effects, or symptoms women may attribute (or misattribute) to the AI, are helpful at each follow-up consultation
Support network often thinks the woman has completed cancer treatment	Include the support person: When a support person is present at appointments, include him or her in introduction of the need for future AI therapy as well as follow-up discussions to increase knowledge of and support for persistence
Women may be receiving HRT at time of diagnosis	Know HRT status: Special attention is needed for women who have recently stopped HRT; they may experience more hot flashes and other symptoms and need more support
Women engage in tip sharing with fellow survivors	Explore self-management attempts: Previous self-management attempts and sources of information can provide information about a woman’s preferences
Women value practical knowledge over additional medication	Expand self-management knowledge: Offering practical, nonpharmacologic tips that women can implement in their daily lives can promote AI persistence
Women who persist with AI may also be considering early discontinuation	Beware of tipping points: Asking women about the most distressing aspects of the AI and whether they have thought about stopping can support persistence

Abbreviations: AI, aromatase inhibitor; HRT, hormone replacement therapy.

for early discontinuation and poorer outcomes. High-quality survivorship care that includes patient monitoring, patient education, adverse effect management, and encouragement may be helpful in ensuring safety and promoting persistence for the prescribed duration.²⁵ According to the American Society of Clinical Oncology guideline, patient-provider communication about AIs should include a discussion of anticipated adverse effects, inquiry about adverse effects, and discussion of possible ways to mitigate them during subsequent appointments.²⁶ Within the limitations of our study, including a small sample limited to one geographic region of the country, our results suggest the need for AI-specific education, support, and practical self-management strategies to improve both medication persistence and quality of life and promote healthy survivorship. On the basis of our observations, we offer some possible strategies to enhance clinical management and adherence as well as inform the development of future interventions for older women receiving AI therapy (Table 4).

Our findings are relevant to both oncology providers as well as providers in other settings who care for this group of women as they navigate complex decisions in the period after primary treatment. From a gero-oncology perspective, our results lay groundwork in understanding older women's decisional processes related to AIs in the words of the women themselves. It is essential that future research incorporate a gerontology-focused approach in the development, implementation, and evaluation of models of care that will promote continuation and adherence throughout the AI trajectory. **JOP**

Acknowledgment

Supported by National Cancer Institute Grant No. R21CA167218-01A1. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of an institution or sponsor. We thank Miriam Slevin, RN, MS, OCN, for her input in the preparation of this manuscript.

Authors' Disclosures of Potential Conflicts of Interest

Disclosures provided by the authors are available with this article at jop.ascopubs.org.

Author Contributions

Conception and design: Patricia A. Ganz, Huibrie C. Pieters

Collection and assembly of data: Huibrie C. Pieters

Data analysis and interpretation: Eden R. Brauer, Huibrie C. Pieters

Manuscript writing: All authors

Final approval of manuscript: All authors

Corresponding author: Huibrie C. Pieters, PhD, DPhil, RN, School of Nursing, Tiverton Ave #4-956, University of California Los Angeles, Los Angeles, CA 90095; e-mail: hpieters@sonnet.ucla.edu.

References

1. Mariotto AB, Yabroff KR, Shao Y, et al: Projections of the cost of cancer care in the United States: 2010-2020. *J Natl Cancer Inst* 103:117-128, 2011
2. DeSantis CE, Fedewa SA, Goding Sauer A, et al: Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. *CA Cancer J Clin* 66:31-42, 2016
3. Howlader N, Noone AM, Krapcho M, et al: SEER Cancer Statistics Review, 1975-2012. Bethesda, MD, National Cancer Institute, 2015
4. Hershman DL, Shao T, Kushi LH, et al: Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. *Breast Cancer Res Treat* 126:529-537, 2011
5. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. *Lancet* 365:1687-1717, 2005
6. Burstein HJ: Aromatase inhibitor-associated arthralgia syndrome. *Breast* 16: 223-234, 2007
7. Burstein HJ, Prestrud AA, Seidenfeld J, et al: American Society of Clinical Oncology clinical practice guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. *J Clin Oncol* 28:3784-3796, 2010
8. Biganzoli L, Wildiers H, Oakman C, et al: Management of elderly patients with breast cancer: Updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). *Lancet Oncol* 13:e148-e160, 2012
9. Henry NL, Azzouz F, Desta Z, et al: Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. *J Clin Oncol* 30:936-942, 2012
10. Murphy CC, Bartholomew LK, Carpentier MY, et al: Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: A systematic review. *Breast Cancer Res Treat* 134:459-478, 2012
11. Owusu C, Buist DS, Field TS, et al: Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. *J Clin Oncol* 26: 549-555, 2008
12. He W, Fang F, Varnum C, et al: Predictors of discontinuation of adjuvant hormone therapy in patients with breast cancer. *J Clin Oncol* 33:2262-2269, 2015
13. Puts MT, Tu HA, Tourangeau A, et al: Factors influencing adherence to cancer treatment in older adults with cancer: A systematic review. *Ann Oncol* 25:564-577, 2014
14. Gibson LJ, Dawson C, Lawrence DH, et al: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. *Cochrane Database Syst Rev* 1: CD003370, 2007
15. Bender CM, Gentry AL, Brufsky AM, et al: Influence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast cancer. *Oncol Nurs Forum* 41:274-285, 2014
16. Lee HS, Lee JY, Ah YM, et al: Low adherence to upfront and extended adjuvant letrozole therapy among early breast cancer patients in a clinical practice setting. *Oncology* 86:340-349, 2014
17. Stanton AL, Petrie KJ, Partridge AH: Contributors to nonadherence and non-persistence with endocrine therapy in breast cancer survivors recruited from an online research registry. *Breast Cancer Res Treat* 145:525-534, 2014
18. Ganz PA: Survivorship: Adult cancer survivors. *Prim Care* 36:721-741, 2009
19. Mullan F: Seasons of survival: Reflections of a physician with cancer. *N Engl J Med* 313:270-273, 1985
20. Harrow A, Dryden R, McCowan C, et al: A hard pill to swallow: A qualitative study of women's experiences of adjuvant endocrine therapy for breast cancer. *BMJ Open* 4:e005285, 2014
21. Pellegrini I, Sarradon-Eck A, Soussan PB, et al: Women's perceptions and experience of adjuvant tamoxifen therapy account for their adherence: Breast cancer patients' point of view. *Psychooncology* 19:472-479, 2010
22. Charmaz K: *Constructing Grounded Theory* (ed 2). Thousand Oaks, CA, Sage Publications, 2014

- 23.** Creswell JW: Qualitative Inquiry and Research Design Choosing Among Five Traditions. Thousand Oaks, CA, Sage Publications, 1998
- 24.** Fink AK, Gurwitz J, Rakowski W, et al: Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. *J Clin Oncol* 22:3309-3315, 2004
- 25.** Levit L, Balogh E, Nass S, et al: Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis. Washington, DC, National Academies Press, 2013
- 26.** Burstein HJ, Temin S, Anderson H, et al: Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. *J Clin Oncol* 32:2255-2269, 2014

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

“Winging It”: How Older Breast Cancer Survivors Persist With Aromatase Inhibitor Treatment

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or jop.ascopubs.org/site/misc/ifc.xhtml.

Eden R. Brauer

No relationship to disclose

Huibrie C. Pieters

No relationship to disclose

Patricia A. Ganz

Leadership: Intrinsic LifeSciences (I)

Stock or Other Ownership: Xenon Pharma (I), Intrinsic LifeSciences (I), Silarus Therapeutics (I), Merganser Biotech (I), TEVA Pharmaceuticals Industries, Novartis, Merck, Johnson & Johnson, Pfizer, GlaxoSmithKline, Abbott Laboratories

Consulting or Advisory Role: Keryx (I), Merganser Biotech (I), Silarus Therapeutics (I), InformedDNA, Vifor Pharma (I)

Research Funding: Keryx (I)

Patents, Royalties, Other Intellectual Property: Patent related to iron metabolism and anemia of chronic disease (I), Up-to-Date royalties for section editor on survivorship

Travel, Accommodations, Expenses: Intrinsic LifeSciences (I), Keryx (I)